Therapeutic Asset Ratings

515 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
su011248 Protein Kinase Inhibitors	AstraZeneca	P3	B (59)
Atirmociclib Metastatic Breast Cancer	AstraZeneca	P2	B (59)
Carboplatin Esophageal Squamous Cell Carcinoma	AstraZeneca	P2	B (59)
azd0120 Multiple Myeloma	AstraZeneca	P3	B (58)
azd5305 Prostate Cancer	AstraZeneca	P3	B (58)
Volrustomig Non-small Cell Lung Cancer	AstraZeneca	P3	B (58)
Capecitabine Prostate Cancer Metastatic	AstraZeneca	P2	B (58)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Ovarian Cancer	AstraZeneca	P2	B (58)
Durvalumab Gastroesophageal Cancer	AstraZeneca	P2	B (58)
LENVATINIB Biliary Tract Cancer	AstraZeneca	P2	B (58)
Cobalamin Non Small Cell Lung Cancer	AstraZeneca	P3	B (57)
Olaparib Newly Diagnosed	AstraZeneca	P3	B (57)
Volrustomig Advanced Clear Cell Renal Cell Carcinoma	AstraZeneca	P3	B (57)
Capivasertib Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	AstraZeneca	P2	B (57)
Mitiperstat Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis	AstraZeneca	P2	B (57)
Zemirciclib Relapsed/Refractory Classical Hodgkins Lymphoma	AstraZeneca	P2	B (57)
Zemirciclib Relapsed/Refractory Peripheral T-cell Lymphoma	AstraZeneca	P2	B (57)
Acalabrutinib Part1: Advanced B-cell Malignancies	AstraZeneca	P1/2	B (57)
Camizestrant ER+ HER2- Advanced Breast Cancer	AstraZeneca	P1/2	B (57)
azd2265 Metastatic Castration-resistant Prostate Cancer	AstraZeneca	P3	B (56)
Puxitatug Samrotecan Endometrial Cancer	AstraZeneca	P3	B (56)
Rilvegostomig Hepatocellular Carcinoma	AstraZeneca	P3	B (56)
Trastuzumab Deruxtecan Endometrial Cancer	AstraZeneca	P3	B (56)
VOLITINIB Solid Tumors	AstraZeneca	P3	B (56)
FLUOROURACILUM Cervical Cancer	AstraZeneca	P2	B (56)

Showing 101 to 125 of 515 assets

PreviousPage 5 of 21Next